Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 5
1983 6
1984 2
1986 3
1988 1
1989 5
1991 2
1992 1
1993 9
1994 14
1995 8
1996 16
1997 13
1998 16
1999 9
2000 14
2001 6
2002 11
2003 12
2004 2
2005 6
2006 8
2007 3
2008 10
2009 9
2010 5
2011 13
2012 11
2013 9
2014 9
2015 18
2016 13
2017 19
2018 11
2019 3
2020 13
2021 10
2022 13
2023 21
2024 15
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Results by year

Filters applied: . Clear all
Page 1
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Van Dao T, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK. Rimassa L, et al. Among authors: jeng lb. J Hepatol. 2025 Oct;83(4):899-908. doi: 10.1016/j.jhep.2025.03.033. Epub 2025 Apr 11. J Hepatol. 2025. PMID: 40222621 Free article. Clinical Trial.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Reply.
Li PC, Thorat A, Jeng LB. Li PC, et al. Among authors: jeng lb. Liver Transpl. 2017 Aug;23(8):1083-1084. doi: 10.1002/lt.24792. Epub 2017 Jul 3. Liver Transpl. 2017. PMID: 28590599 No abstract available.
Harnessing the Power of Sugar-Based Nanoparticles: A Drug-Free Approach to Enhance Immune Checkpoint Inhibition against Glioblastoma and Pancreatic Cancer.
Hsu FT, Chen YT, Chin YC, Chang LC, Chiang SC, Yang LX, Liu HS, Yueh PF, Tu HL, He RY, Jeng LB, Shyu WC, Hu SH, Chiang IT, Liu YC, Chiu YC, Wu GC, Yu CC, Su WP, Huang CC. Hsu FT, et al. Among authors: jeng lb. ACS Nano. 2024 Oct 22;18(42):28764-28781. doi: 10.1021/acsnano.4c07903. Epub 2024 Oct 9. ACS Nano. 2024. PMID: 39383310
Integrated genomic analyses of hepatocellular carcinoma.
Chang YS, Tu SJ, Chen HD, Hsu MH, Chen YC, Chao DS, Chung CC, Chou YP, Chang CM, Lee YT, Yen JC, Jeng LB, Chang JG. Chang YS, et al. Among authors: jeng lb. Hepatol Int. 2023 Feb;17(1):97-111. doi: 10.1007/s12072-022-10455-z. Epub 2022 Dec 6. Hepatol Int. 2023. PMID: 36472800
371 results